High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

Pediatric Blood and Cancer

Volumn 44, Issue 4, 2005, Pages 348-357

  Pritchard, Jon ^a,b   Cotterill, Simon J ^c   Germond, Shirley M ^a,b   Imeson, John ^d   De Kraker, Jan ^e   Jones, David R ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d United Kingdom Children's Cancer Study Group   (United Kingdom)

^e Apotheek Academish   (Netherlands)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

High dose melphalan; Randomised trial; Stage 3 and 4 neuroblastoma; Survival; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIPODOPHYLLOTOXIN; MELPHALAN; VINCRISTINE SULFATE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; ESOPHAGUS ULCER; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEMATEMESIS; HUMAN; ILEUS; INFANT; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROBLASTOMA; NUTRITIONAL DISORDER; PLEURA CAVITY; PLEURA DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTICEMIA; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INFANT; LIFE TABLES; MALE; MELPHALAN; NEUROBLASTOMA; SURVIVAL RATE;

EID: 14644397910     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20219     Document Type: Article

References (43)

1. Finklestein JZ, Klemperer MR, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma: A report from Childrens Cancer Study Group. Med Fed Oncol 1979;6:179-188.
2. Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981;48:2310-2317.
3. Ninane J. Pritchard J, Malpas JS. Chemotherapy of advanced neuroblastoma: Does adriamycin contribute? Arch Dis Child 1981;56:544-548.
4. Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 1984;2:742-747.
5. Sawaguchi S, Kaneko M, Uchino J, et al. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan. Cancer 1990;66:1879-1887.
6. Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 2000;36:901-908.
7. Pritchard J, Whelan R, Hill BT. Sequential cis-platinum and VM26 in neuroblastoma: Laboratory an clinical (OPEC regimen) studies. In: Evans AE, D'Angio GJ, Seeger R, editors. Recent advances in neuroblastoma research. New York: AR Liss; 1985. pp 545-555.
8. Pritchard J, Kiely E, Rogers DW, et al. Long-term survival after advanced neuroblastoma. New Engl J Med 1987;317:1026-1027.
9. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
10. Hill BT, Whelan RDH. Assessments of the sensitivities of cultured human neuroblastoma cells to anti-tumor drugs. Pediatr Res 1981;15:1117-1122.
11. Pritchard J, McElwain TJ, Graham Pole J. High dose melphalan with autologous bone marrow for treatment of advanced neuroblastoma. Br J Cancer 1982;45:86-94.
12. Pritchard J. Megatherapy for advanced neuroblastoma: Rationale & role. Eur J Cancer 1995;31A:134-136.
13. Graham-Pole J, Lazarus HM, Herzig RH, et al. High dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing sarcoma. Am J Ped Hemat Oncol 1984;6:17-26.
14. de Kraker J, Voute PA. The effect of high dose melphalan with autologous bone marrow transplantation in neuroblastoma patients with advanced disease. In: McVie JG, Dalesio O, Smith IE, editors. Autologous bone marrow transplantation and solid tumors. New York: Raven Press; 1984. pp 153-156.
15. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971;27:374-378.
16. Pinkerton CR, Pritchard J, de Kraker J, et al. ENSG1: Randomised study of high dose melphalan in neuroblastoma. In: Dicke K, Spitzer G, Jugannoth S, editors. Autologous bone marrow transplantation. Texas: University of Texas Press; 1987.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revision of the International criteria for neuroblastoma diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1993:11:1466-1477.
18. Franklin IM, Pritchard J. Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies. J Clin Pathol 1983:36:1215-1218.
19. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971;1:1046-1049.
20. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37:849-857.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977;35:1-39.
22. Kay R, Schumacher M. Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials. Stat Med 1983;2:41-58.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I Introduction and design. Br J Cancer 1976;34:585-612.
24. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Chapter 4. New York: Wiley; 1980. pp 70-76 and 87-98.
25. Pinkerton R, Philip T, Bouffet E, et al. Autologous bone marrow transplantation in paediatric solid tumors. Clin Haem 1986;15:187-203.
26. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984;2:609-616.
27. Hartmann O, Kalifa C, Benhamou E, et al. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 1986;16:165-169.
28. Philip T, Bernard JL, Zucker JM, et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987:5:266-271.
29. Kushner BH, O'Reilly RJ, Mandell LR, et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991:9:274-279.
30. Corbett R, Pinkerton R, Pritchard J, et al. High dose vincristine, etoposide, carboplatin, and melphalan with autologous bone marrow transplantation: Results of a pilot study. Eur J Cancer 1992:28A:1324-1328.
31. Gordon SJ, Pearson AD, Reid MM. Toxicity of single-day high-dose vincristine, melphalan, etoposide, and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992;28A:1319-1323.
32. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol 1983:1:517-531.
33. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
34. Pritchard-Jones K, Mitchell CD, Shannon R, et al. Reasons for non-randomization in the UKW3 Trial of surgical approach in localised Wilms' tumor. Med Pediatr Oncol 2003;41:257 (abstract).
35. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Eng J Med 1991:325:1608-1614.
36. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
37. Pearson ADJ, Craft AW, Pinkerton CR, et al. High dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992;28A:1654-1659.
38. Cotterill SJ, Pearson ADJ, Pritchard J, et al. Late relapse and prognosis for neuroblastoma patients surviving five years or more. A report from the European Neuroblastoma Study Group "Survey". Med Pediatr Oncol 2001;36:235-238.
39. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999:17:2264-2279.
40. Castleberry RP. Neuroblastoma. Eur J Cancer 1997:33:1430-1437.
41. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-1961.
42. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 1994:12:2382-2389.
43. Kremens B, Simon R, Neithammer D, et al. Stem cell transplantation versus maintenance chemotherapy in neuroblastoma: A randomized trial of the GPOH Group. Med Padiatr Oncol 2003;41:286 (abstract).